Clinical Trials Using MDM2/MDMX Inhibitor ALRN-6924
Clinical trials are research studies that involve people. The clinical trials on this list are studying MDM2/MDMX Inhibitor ALRN-6924. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.
Location: 11 locations
ALRN-6924 in Treating Children with Recurrent or Refractory Solid Tumors, Brain Tumors, or Lymphoma
This phase I trial studies the best dose and side effects of ALRN-6924 in children with solid tumors, brain tumors, or lymphoma that have come back or do not respond to treatment. ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX and may stop tumor growth and may cause tumor cells to die.
Location: 3 locations
ALRN-6924 and Paclitaxel in Treating Patients with Advanced, Metastatic, or Unresectable Solid Tumors
This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ALRN-6924 and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Location: M D Anderson Cancer Center, Houston, Texas